10. Use of a hydroxy-derivative of atorvastatin or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cardiovascular-related disease, wherein the medicament further comprises an oil comprising eicosapentaenoic acid or derivative thereof.

11. The use of claim 10 wherein the eicosapentaenoic acid or derivative thereof comprises ethyl eicosapentaenoate.

12. The use of claim 11 wherein the oil comprises at least 95% by weight of the ethyl eicosapentaenoate.

13. The use of claim 10 wherein the oil comprises eicosapentaenoic acid in free acid form.

14. The use of claim 13 wherein the oil comprises at least 95% by weight of the eicosapentaenoic acid in free acid form.

15. The use of claim 10 wherein the hydroxy-derivative of atorvastatin or pharmaceutically acceptable salt thereof is selected from ortho or para hydroxy atorvastatin and pharmaceutically acceptable salts thereof.

16. The ~~method~~ use of claim 10 wherein the hydroxy-derivative of a statin or pharmaceutically acceptable salt thereof is selected from o-hydroxy atorvastatin, p-hydroxy atorvastatin, p-hydroxy atorvastatin calcium, p-hydroxy atorvastatin disodium, o-hydroxy atorvastatin calcium, o-hydroxy atorvastatin lactone, o-hydroxy atorvastatin-d5 calcium, o-hydroxy atorvastatin-d5 disodium, o-hydroxy atorvastatin-d5 lactone, 2-hydroxy atorvastatin bisodium p-hydroxy atorvastatin lactone, p-hydroxy atorvastatin~d5 calcium, p-hydroxy atorvastatin-d5 lactone, and 4-hydroxy atorvastatin bisodium.

17. The use of claim 10 wherein the cardiovascular disease is selected from hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, and myocardial infarction.

18. The use of claim 10 wherein the cardiovascular disease is atherosclerosis.